Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on innovative cancer therapies, announced on March 24, 2026, that it has entered into a Securities Purchase Agreement with RA Capital Management. This private placement is expected to yield gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses. Additionally, the company could secure an extra $44 million if accompanying warrants are fully exercised. Under the terms of the agreement, Karyopharm will issue 1,030,354 shares of its common stock at a price of $6.785 per share, alongside pre-funded warrants and accompanying warrants to purchase additional shares. The pre-funded warrants will have an exercise price of $0.0001 and will be immediately exercisable without expiration. The closing of this private placement is anticipated to occur on or about March 26, 2026, subject to customary closing conditions. The proceeds from this placement are intended for general corporate purposes, including ongoing and planned clinical trial activities. Karyopharm's recent Phase 3 SENTRY trial results, which demonstrated significant improvements in spleen volume reduction for patients with myelofibrosis, further bolster the company's position in the oncology market. The company plans to utilize the funds to enhance its clinical trial efforts and potentially expand its product offerings in the future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.